logo BDSP

Base documentaire

Fermeture du portail BDSP le 1er juillet 2019. En savoir plus...

  1. Dual Peroxisome Proliferator-Activated Receptor alpha/delta Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects.

    Article (Document papier) - En anglais


    The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes.

    We investigated the effect of GFT505, a dual peroxisome proliferator-activated receptor (PPAR) - alpha/delta agonist, on peripheral and hepatic insulin sensitivity.

    RESEARCH DESIGN AND METHODS-Twenty-two abdominally obese insulin-resistant males (homeostasis model assessment of insulin resistance>3) were randomly assigned in a randomized crossover study to subsequent 8-week treatment periods with GFT505 (80 mg/day) or placebo, followed by a two-step hyperinsulinemic-euglycemic insulin clamp with a glucose tracer to calculate endogenous glucose production (EGP).

    The primary end point was the improvement in glucose infusion rate (GIR).

    Gene expression analysis was performed on skeletal muscle biopsy specimens.


    GFT505 improved peripheral insulin sensitivity, with a 21% (P=0.048) increase of the GIR at the second insulin infusion period.

    GFT505 also enhanced hepatic insulin sensitivity, with a 44% (P=0.006) increase of insulin suppression of EGP at the first insulin infusion period.

    Insulin-suppressed plasma free fatty acid concentrations were significantly reduced on GFT505 treatment (0.21 ± 0.07 vs.0.27 ± 0.11 mmol/L ; P=0.006).

    Neither PPARalpha nor PPARdelta target genes were induced in skeletal muscle, suggesting a liver-targeted action of GFT505.

    GFT505 significantly reduced fasting plasma triglycerides (-21% ; P=0.003) and LDL cholesterol (-13% ; P=0.0006), as well as liver enzyme concentrations (gamma-glutamyltranspeptidase : - 30.4%, P=0.003 ; alanine aminotransferase : - 20.5%, P=0.004).

    There was no safety concern or any indication of PPAR-gamma activation with GFT505.

    CONCLUSIONS-The dual PPARalpha/delta agonist GFT505 is a liver-targeted insulin-sensitizer that is a promising drug candidate for the treatment of type 2 diabetes and nonalcoholic fatty liver disease.

    Mots-clés Pascal : Obésité, Récepteur PPAR-alpha, Agoniste, Amélioration, Foie, Insuline, Homme, Endocrinologie, Maladie métabolique, Nutrition, Etat nutritionnel, Sensibilité à l'insuline, Appareil digestif, Hormone pancréatique, Trouble de la nutrition

    Mots-clés Pascal anglais : Obesity, PPAR-alpha receptor, Agonist, Improvement, Liver, Insulin, Human, Endocrinology, Metabolic diseases, Nutrition, Nutritional status, Insulin sensitivity, Digestive system, Pancreatic hormone, Nutrition disorder

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 13-0326241

    Code Inist : 002B21E01. Création : 20/12/2013.

Fermeture du portail BDSP le 1er juillet 2019

Nous avons le regret de vous informer de la fermeture du portail BDSP le 1er juillet 2019. Du 1er janvier au 30 juin 2019, le site et ses services resteront accessibles mais ne seront plus alimentés, ni mis à jour. En savoir plus...